Transvenous electrical cardioversion of atrial fibrillation in horses: Horse and procedural factors correlated with success and recurrence.
amiodarone
arrhythmia
cardiology
equine
sotalol
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
07
02
2022
received:
07
04
2021
accepted:
08
02
2022
pubmed:
6
3
2022
medline:
1
4
2022
entrez:
5
3
2022
Statut:
ppublish
Résumé
Transvenous electrical cardioversion (TVEC) is 1 of the main treatment options for atrial fibrillation (AF) in horses. Large-scale studies on factors affecting success and prognosis have primarily been performed in Standardbred populations. To determine factors affecting cardioversion success, cardioversion difficulty and recurrence in a predominant Warmblood study sample. TVEC records of 199 horses. Retrospective study of TVEC procedures of horses admitted for AF without severe echocardiographic abnormalities. Horse and procedural factors for success and cumulative amount of energy (≤ 600 J vs > 600 J) were determined using multivariable logistic regression. A survival analysis was performed to determine risk factors for recurrence. Two hundred and thirty-one TVEC procedures were included, with a 94.4% success rate and 31.9% recurrence rate (51/160). Mitral regurgitation (OR 0.151, 95% CI 0.032-0.715, P = .02) and AF cycle length (OR 1.05, 95% CI 1.01-1.09, P = .02) were independent determinants for success. Catheter type (OR 0.154, 95% CI 0.074-0.322, P < .001), previous AF episode (OR 3.10, 95% CI 1.20-8.01, P = .02), tricuspid regurgitation (OR 2.54, 95% CI 1.25-5.13, P = .01), and body weight (OR 1.009, 95% CI 1.003-1.015, P = .004) were significantly correlated with cumulative amount of energy delivered. Significant risk factors for recurrence after a first AF episode were sex (stallion; HR 3.05, 95% CI 1.34-6.95, P = .008), mitral regurgitation (HR 1.91, 95% CI 1.08-3.38, P = .03), and AF duration (HR 1.001, 95% CI 1.0001-1.0026, P = .04). Both horse and procedural factors should be considered when assessing treatment options and prognosis in horses with AF.
Sections du résumé
BACKGROUND
BACKGROUND
Transvenous electrical cardioversion (TVEC) is 1 of the main treatment options for atrial fibrillation (AF) in horses. Large-scale studies on factors affecting success and prognosis have primarily been performed in Standardbred populations.
HYPOTHESIS/OBJECTIVES
OBJECTIVE
To determine factors affecting cardioversion success, cardioversion difficulty and recurrence in a predominant Warmblood study sample.
ANIMALS
METHODS
TVEC records of 199 horses.
METHODS
METHODS
Retrospective study of TVEC procedures of horses admitted for AF without severe echocardiographic abnormalities. Horse and procedural factors for success and cumulative amount of energy (≤ 600 J vs > 600 J) were determined using multivariable logistic regression. A survival analysis was performed to determine risk factors for recurrence.
RESULTS
RESULTS
Two hundred and thirty-one TVEC procedures were included, with a 94.4% success rate and 31.9% recurrence rate (51/160). Mitral regurgitation (OR 0.151, 95% CI 0.032-0.715, P = .02) and AF cycle length (OR 1.05, 95% CI 1.01-1.09, P = .02) were independent determinants for success. Catheter type (OR 0.154, 95% CI 0.074-0.322, P < .001), previous AF episode (OR 3.10, 95% CI 1.20-8.01, P = .02), tricuspid regurgitation (OR 2.54, 95% CI 1.25-5.13, P = .01), and body weight (OR 1.009, 95% CI 1.003-1.015, P = .004) were significantly correlated with cumulative amount of energy delivered. Significant risk factors for recurrence after a first AF episode were sex (stallion; HR 3.05, 95% CI 1.34-6.95, P = .008), mitral regurgitation (HR 1.91, 95% CI 1.08-3.38, P = .03), and AF duration (HR 1.001, 95% CI 1.0001-1.0026, P = .04).
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Both horse and procedural factors should be considered when assessing treatment options and prognosis in horses with AF.
Identifiants
pubmed: 35246994
doi: 10.1111/jvim.16395
pmc: PMC8965264
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-769Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S56217N
Informations de copyright
© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Equine Vet J. 1971 Jan;3(1):56-64
pubmed: 5161359
Equine Vet J. 2020 May;52(3):374-378
pubmed: 31583742
J Vet Intern Med. 2008 Nov-Dec;22(6):1353-9
pubmed: 19000247
J Am Coll Cardiol. 1999 Apr;33(5):1217-26
pubmed: 10193719
Vet J. 2021 Feb;268:105594
pubmed: 33468306
Vet J. 2006 Jul;172(1):129-34
pubmed: 15908245
Eur Heart J. 2000 Jan;21(1):66-73
pubmed: 10610746
J Cardiovasc Electrophysiol. 1998 Feb;9(2):122-8
pubmed: 9511886
J Interv Card Electrophysiol. 2004 Jun;10(3):221-6
pubmed: 15133358
Heart Rhythm. 2007 Aug;4(8):1048-56
pubmed: 17675080
J Vet Intern Med. 2018 Mar;32(2):815-821
pubmed: 29460446
Steroids. 2010 Oct;75(10):676-84
pubmed: 20420845
Circulation. 2000 Sep 19;102(12):1454-60
pubmed: 10993867
Vet J. 2020 Sep;263:105521
pubmed: 32928494
Vet J. 2020 Sep;263:105519
pubmed: 32928488
Drugs. 1992 Jan;43(1):69-110
pubmed: 1372862
J Vet Intern Med. 2014 Mar-Apr;28(2):624-9
pubmed: 24611990
Vet J. 2005 Jul;170(1):124-7
pubmed: 15993796
J Cardiovasc Electrophysiol. 2001 Sep;12(9):986-9
pubmed: 11573707
Cardiovasc Res. 1999 May;42(2):470-6
pubmed: 10533582
Am Heart J. 2000 Oct;140(4):678-83
pubmed: 11011345
Int J Cardiol. 2006 Jan 13;106(2):268-9
pubmed: 16321704
Equine Vet J. 2018 May;50(3):377-383
pubmed: 29023952
Can J Cardiol. 2021 Sep;37(9):1322-1331
pubmed: 33276049
Pacing Clin Electrophysiol. 2001 Aug;24(8 Pt 1):1208-15
pubmed: 11523605
J Am Coll Cardiol. 2017 May 23;69(20):2488-2497
pubmed: 28521886
J Am Vet Med Assoc. 2018 Jun 1;252(11):1409-1414
pubmed: 29772981
J Vet Intern Med. 2015 May-Jun;29(3):946-53
pubmed: 25917409
Am Heart J. 2006 Jul;152(1):155.e9-13
pubmed: 16824847
Equine Vet J. 2004 Nov;36(7):609-14
pubmed: 15581326
Equine Vet J. 2014 Mar;46(2):174-9
pubmed: 23738919
Vet Med (Auckl). 2015 Feb 26;6:83-90
pubmed: 30101098
Vet J. 2016 Apr;210:34-8
pubmed: 26900009
J Vet Intern Med. 2008 May-Jun;22(3):609-15
pubmed: 18466256
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Can J Vet Res. 2000 Oct;64(4):254-8
pubmed: 11041507
Pacing Clin Electrophysiol. 2003 Sep;26(9):1809-14
pubmed: 12930494
J Vet Intern Med. 2014 May-Jun;28(3):749-61
pubmed: 24628586
J Vet Cardiol. 2021 Apr;34:73-79
pubmed: 33611234
J Am Coll Cardiol. 1993 Oct;22(4):1199-206
pubmed: 8409061
N Engl J Med. 2005 May 5;352(18):1861-72
pubmed: 15872201
J Vet Intern Med. 1988 Jan-Mar;2(1):1-6
pubmed: 3221350
Equine Vet J. 2013 Sep;45(5):552-7
pubmed: 23294231
J Vet Intern Med. 2020 Nov;34(6):2701-2709
pubmed: 33098342
Physiol Behav. 1981 Oct;27(4):637-40
pubmed: 7323166
Vet J. 2008 Aug;177(2):198-204
pubmed: 17920965
J Cardiovasc Electrophysiol. 2002 Mar;13(3):267-75
pubmed: 11942596
J Vet Intern Med. 2005 Sep-Oct;19(5):695-702
pubmed: 16231714
Equine Vet J. 2016 Jan;48(1):21-6
pubmed: 25266765
Equine Vet J. 2017 Jan;49(1):58-64
pubmed: 26729051
J Pharmacol Exp Ther. 1998 May;285(2):672-9
pubmed: 9580612
J Vet Intern Med. 1995 Mar-Apr;9(2):57-67
pubmed: 7760311
Vet J. 2013 Sep;197(3):583-8
pubmed: 23823082
J Vet Cardiol. 2005 Nov;7(2):109-19
pubmed: 19083326
J Vet Intern Med. 2022 Mar;36(2):758-769
pubmed: 35246994
Vet Clin North Am Equine Pract. 2019 Apr;35(1):43-64
pubmed: 30826106
Am J Vet Res. 2011 Sep;72(9):1193-203
pubmed: 21879977
Cardiovasc Res. 2002 Feb 15;53(3):752-62
pubmed: 11861045
J Am Vet Med Assoc. 1982 Feb 1;180(3):261-5
pubmed: 7056674
Vet Anaesth Analg. 2002 Oct;29(4):159-170
pubmed: 28404360
Pacing Clin Electrophysiol. 2002 Aug;25(8):1179-84
pubmed: 12358167
Circulation. 1995 Oct 1;92(7):1954-68
pubmed: 7671380
BMC Cardiovasc Disord. 2019 Oct 21;19(1):228
pubmed: 31638896